A Phase II Study of MK-8669 When Administered as Maintenance Therapy to Japanese Patients With Metastatic Bone or Soft-tissue Sarcomas
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2013
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Bone cancer; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2012 Planned End Date changed from 1 Oct 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.